Patents by Inventor Jiaxi WU

Jiaxi WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250114468
    Abstract: The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a PD1 inhibitor (e.g., an anti-PD1 antibody). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.
    Type: Application
    Filed: October 8, 2024
    Publication date: April 10, 2025
    Inventors: Jiaxi Wu, Ramandeep Bhavsar
  • Publication number: 20250114469
    Abstract: The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a TAAxCD3 bispecific antibody. The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.
    Type: Application
    Filed: October 8, 2024
    Publication date: April 10, 2025
    Inventors: Jiaxi Wu, Alison Crawford
  • Publication number: 20250066441
    Abstract: The present disclosure relates to IL 12 receptor agonists with improved therapeutic profiles.
    Type: Application
    Filed: July 18, 2022
    Publication date: February 27, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Aaron CHANG, Jiaxi WU, Tong ZHANG, Nicolin BLOCH, Erica ULLMAN, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • Patent number: 12215131
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: February 4, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
  • Publication number: 20250034224
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: April 5, 2024
    Publication date: January 30, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric Smith, Chia-Yang LIN, Thomas Craig Meagher
  • Patent number: 12168681
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: December 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Publication number: 20240400632
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: August 19, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Publication number: 20240376229
    Abstract: The present disclosure provides interferon (IFN) receptor antagonists. IFN receptor antagonists disclosed herein comprise an anchoring moiety, an IFN masking moiety, an IFN moiety, and a separator moiety, e.g., a targeting moiety that recognizes an antigen associated with cells expressing Type 1 interferon receptors and anchors the IFN receptor antagonist to such cells. The disclosure further provides pharmaceutical compositions comprising the IFN receptor antagonists, and methods of use of the IFN receptor antagonists in IFN signaling inhibition, including treatment methods. Also disclosed are nucleic acids encoding the IFN receptor antagonists, recombinant cells that express the IFN receptor antagonists, and methods of producing the IFN receptor antagonists.
    Type: Application
    Filed: May 10, 2024
    Publication date: November 14, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Vidur GARG, Nicolin BLOCH, Erica ULLMAN, Eva-Maria WEICK, Jiaxi WU, Tong ZHANG, Eric SMITH, Aynur HERMANN, Chia-Yang LIN
  • Patent number: 12091440
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: September 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
  • Publication number: 20240270836
    Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.
    Type: Application
    Filed: January 12, 2024
    Publication date: August 15, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Aaron CHANG, Jiaxi WU, Supriya PATEL, Tong ZHANG, Samuel DAVIS, Saida DADI-MEHMETAJ
  • Publication number: 20240148867
    Abstract: The present disclosure relates to methods of increasing the efficacy of adoptive cell therapy (ACT) and methods of treating cancer, wherein the methods include administering to a subject with cancer in need thereof a combination therapy comprising a therapeutically effective amount of an ACT (e.g., an immune cell comprising a modified T cell receptor (TCR) against a tumor-associated antigen (TAA), or a chimeric antigen receptor (CAR) against a TAA) and a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival, as compared to a subject administered the ACT as monotherapy or the ACT in combination with a non-targeted immunocytokine.
    Type: Application
    Filed: October 30, 2023
    Publication date: May 9, 2024
    Inventors: David DiLillo, Jiaxi Wu
  • Publication number: 20240101633
    Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 28, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eva-Maria WEICK, Nicolin BLOCH, Vidur GARG, Erica ULLMAN, Tong ZHANG, Chia-Yang LIN, Jiaxi WU, Eric Smith
  • Publication number: 20240067690
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Application
    Filed: October 25, 2023
    Publication date: February 29, 2024
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Publication number: 20240067691
    Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.
    Type: Application
    Filed: August 17, 2023
    Publication date: February 29, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eva-Maria WEICK, Nicolin BLOCH, Vidur GARG, Erica ULLMAN, Tong ZHANG, Chia-Yang LIN, Jiaxi WU, Eric Smith
  • Publication number: 20230391844
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Supriya PATEL, Tong ZHANG, Nicolin BLOCH, Eric SMITH, Chia-Yang LIN, Vidur GARG, Erica ULLMAN
  • Patent number: 11834485
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: December 5, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Publication number: 20230382969
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: May 26, 2023
    Publication date: November 30, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Supriya PATEL, Tong ZHANG, Jiaxi WU, Aaron CHANG, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • Publication number: 20230331800
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: May 9, 2023
    Publication date: October 19, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Publication number: 20230312665
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: April 11, 2023
    Publication date: October 5, 2023
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Patent number: 11725034
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: August 15, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher